News Sosei see Teva pipeline cull as an opportunity Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
UK & Europe Ex-Teva exec to be new Hikma CEO Hikma has a new chief executive after Said Darwazah, the son of the company’s late founder, Samih Darwazah, stepped aside.
News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
